علاج سرطان البنكرياس المتقدم موضعياً غير القابل للاستئصال بسبب الإصابة الوعائية

References

DOI: 10.1016/j.annonc.2023.08.009

In 30%-40% of patients, the tumour is unresectable due to vascular involvement.

In LAPC, the purpose of conversion (or induction) therapy is to induce tumour downsizing to facilitate resection in patients with initial unresectable disease.

A conversion surgery strategy utilising the standard of care of (up to) 6 months of combination ChT (FOLFIRINOX or GN) can be chosen [I, B]; GN is not EMA or FDA approved for LAPC.

Exploration for resection could be discussed if there is a significant decrease in CA 19-9 level, clinical improvement and tumour downstaging [IV, B].

All patients must be evaluated by the local MDTB for resectability every 2-3 months [III, A].

View source ↗